Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Edgestream Partners L.P.

Edgestream Partners L.P. lifted its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 170.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,588 shares of the company's stock after purchasing an additional 117,506 shares during the period. Edgestream Partners L.P. owned about 0.22% of Progyny worth $3,219,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of PGNY. Pacer Advisors Inc. grew its position in shares of Progyny by 12,579.4% in the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after purchasing an additional 2,472,983 shares in the last quarter. Invenomic Capital Management LP acquired a new stake in Progyny during the third quarter worth about $29,509,000. Fort Washington Investment Advisors Inc. OH raised its stake in Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares during the period. Barclays PLC grew its stake in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after buying an additional 594,140 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of Progyny by 227.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 789,418 shares of the company's stock worth $13,231,000 after buying an additional 548,602 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PGNY shares. Truist Financial reissued a "hold" rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lifted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. Finally, Barclays cut their price target on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $24.82.

Progyny Trading Up 0.4 %

Shares of PGNY traded up $0.08 during midday trading on Wednesday, reaching $20.03. 1,936,967 shares of the company were exchanged, compared to its average volume of 1,925,772. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $38.98. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 34.54, a P/E/G ratio of 2.39 and a beta of 1.41. The stock has a 50-day moving average price of $21.43 and a 200-day moving average price of $18.65.

Insider Activity

In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of Progyny stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.